Albert Bourla, Pfizer CEO (Markus Schreiber/AP Images)
April 14, 2025 01:14 PM EDT
Deals
Pharma

What's Pfiz­er's next move af­ter shelv­ing its oral obe­si­ty drug danuglipron?

Elizabeth Cairns

Senior biopharma journalist

On Mon­day, Pfiz­er an­nounced it had giv­en up on danuglipron, the com­pa­ny’s close­ly-watched, once-dai­ly obe­si­ty pill. The move al­most …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump pledges his sup­port for a change to the IRA long sought by drug­mak­ers

J&J's Du­a­to says 'not tar­iffs, but tax pol­i­cy' is best way to boost US man­u­fac­tur­ing

Phar­ma tar­iffs could leave lit­tle room to hide with sweep­ing probe un­der­way

Sanofi’s Kymab-orig­i­nat­ed in­flam­ma­to­ry drug flunks mid-stage asth­ma tri­al

Leqem­bi wins EU au­tho­riza­tion for some Alzheimer's pa­tients, giv­ing Bio­gen, Ei­sai a boost over Lil­ly

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times